CD122 is an integral part of both the interleukin-2 (IL-2) and interleukin-15 (IL-15) receptors. HuABC2 is a humanized anti-CD122 IgG antibody that has a unique function to suppress CD122/CD132-bearing NK and memory T cells, but not CD25/CD122/CD132-bearing Treg cells, which makes HuABC2 suitable for treatment of autoimmune disease and transplant.
In non-human primates, HuABC2 showed a good safety profile, suppressed renewal of CD8+ memory T cells and NK cells, and demonstrated ability to prolong survival of non-human primates receiving life-sustaining kidney allografts. Notably, Treg cells were not suppressed by treatment with HuABC2 (click here for the publication of JN Biosciences' academic collaborators).
ChMBC7, a surrogate of HuABC2, is a rat-mouse chimeric IgG antibody that binds to and blocks the function of mouse CD122. Therapeutic activity of ChMBC7 was demonstrated in mouse disease models of skin allograft, type I diabetes and vitiligo by JN Biosciences' collaborators. Other academic researchers also reported the therapeutic efficacy of an anti-CD122 antibody in the mouse models of celiac disease, type I diabetes and alopecia areata.
HuABC2 is expected to be efficacious for treatment of a variety of immune-mediated diseases in humans, including vitiligo, alopecia areata, type I diabetes, celiac disease, multiple sclerosis, Behcet's disease and organ transplant rejection, in which the involvement of pathogenic NK and CD8+ memory T cells are indicated in the onset and/or maintenance of diesease conditions. A summary of HuABC2 is placed here.
HuABC2 is available for out-licensing. For inquiry, please contact us by email at info(at)jn-bio.com (convert (at) to @).
